Roth Mkm Boosts Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $21.00

Zevra Therapeutics (NASDAQ:ZVRA) had its price target upped by Roth Mkm from $19.00 to $21.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts also recently issued reports on ZVRA. William Blair raised Zevra Therapeutics to a strong-buy rating in a research report on Friday, August 30th. JMP Securities began coverage on Zevra Therapeutics in a report on Tuesday. They issued an outperform rating and a $17.00 price objective for the company. HC Wainwright boosted their price objective on Zevra Therapeutics from $18.00 to $20.00 and gave the company a buy rating in a research note on Friday, September 20th. Maxim Group increased their target price on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a buy rating in a research report on Tuesday. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Zevra Therapeutics in a research note on Wednesday, August 14th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Zevra Therapeutics has an average rating of Buy and an average target price of $21.00.

Zevra Therapeutics Price Performance

ZVRA opened at $7.31 on Tuesday. The firm has a market cap of $384.65 million, a P/E ratio of -5.41 and a beta of 1.94. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $8.95. The firm has a 50-day moving average of $7.14 and a 200 day moving average of $5.76.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The company had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same period in the prior year, the company earned ($0.15) earnings per share. On average, research analysts expect that Zevra Therapeutics will post -1.59 EPS for the current year.

Insider Buying and Selling

In other news, Director Thomas Anderson purchased 10,000 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was purchased at an average cost of $6.81 per share, with a total value of $68,100.00. Following the acquisition, the director now directly owns 20,000 shares in the company, valued at $136,200. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have bought 22,000 shares of company stock valued at $140,340. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC bought a new stake in Zevra Therapeutics during the second quarter valued at approximately $474,000. The Manufacturers Life Insurance Company grew its position in Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after acquiring an additional 2,452 shares in the last quarter. Retirement Planning Co of New England Inc. increased its stake in Zevra Therapeutics by 6.5% in the second quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock valued at $2,246,000 after acquiring an additional 28,107 shares during the last quarter. Mystic Asset Management Inc. raised its position in Zevra Therapeutics by 11.9% during the second quarter. Mystic Asset Management Inc. now owns 297,947 shares of the company’s stock valued at $1,460,000 after purchasing an additional 31,650 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Zevra Therapeutics by 17.9% during the second quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after purchasing an additional 8,619 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.